[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053935":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":52,"collaborators":20,"id":54,"slug":20,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":20,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":20,"enrollmentInfo":62,"targetDuration":20,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":74,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Mahidol University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"study arm","EXPERIMENTAL","olanzapine palonosetron with dexamethasone on day 1 only",[13],"Drug: dexamethasone sparing",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","dexamethasone sparing","omit dexamethasone on day 2-4",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Suthinee Ithimakin","CONTACT","+66898127440","aesi105@yahoo.co.th",[28],{"facility":29,"status":30,"city":31,"state":20,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Faculty of Medicine Siriraj Hospital, Mahidol University","RECRUITING","Bangkok","10700","Thailand","TH",{"type":36,"coordinates":37},"Point",[38,39],100.50144,13.75398,{"lat":39,"lon":38},[42,44,47,50],{"name":23,"role":24,"phone":43,"phoneExt":20,"email":26},"0898127440",{"name":45,"role":46,"phone":20,"phoneExt":20,"email":20},"Sirisopa Techawattanawanna, M.D","PRINCIPAL_INVESTIGATOR",{"name":48,"role":49,"phone":20,"phoneExt":20,"email":20},"Akarin Nimmannit, M.D","SUB_INVESTIGATOR",{"name":51,"role":49,"phone":20,"phoneExt":20,"email":20},"Visullaya Sa-nguanwongwan, M.D",{"type":53,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100053935",false,"NCT07699276","Steroid Sparing Regimen With Olanzapine and Palonosetron for Emetic Prevention for High Dose Cisplatin","Steroid-sparing Regimen With Olanzapine and Ondansetron to Prevent Emesis Caused by High Dose Cisplatin in Solid Cancer Patient : A Single Arm Phase II Study","Inclusion Criteria:\n\n* histologically confirmed solid malignancy\n* scheduled for first cycle of cisplatin at dosage of at least 50 mg\u002Fm2\n\nExclusion Criteria:\n\n* pregnancy\n* pelvic or abdominal radiation within 4 weeks\n* uncontrolled brain metastasis\n* other moderate or high emetic risk chemotherapy on day 2-5\n* untreated gut obstruction\n* known allergy or severe adverse effect from palonosetron or olanzapine\n* AST\u002F ALT \\> 2.5x or serum creatinine clearance less than 50 ml\u002Fmin","ALL","18 Years",{"count":63,"type":64},95,"ESTIMATED","INTERVENTIONAL",[67],"PHASE2","A phase II study evaluating dexamethasone sparing regimen with olanzapine and palonosetron for patients receiving high dose cisplatin to prevent chemotherapy induced nausea and vomiting",[70,71,72,73],"Cancer (Solid Tumors)","Vomiting","Cisplatin","Olanzapine",[75,76,17,77],"cisplatin","chemotherapy induced nausea vomiting","olanzapine","2026-07-07",{"date":80,"type":81},"2026-07-13","ACTUAL",{"date":83,"type":81},"2026-02-10",{"date":85,"type":64},"2027-11-15",{"name":5,"class":6},1]